Crinetics Pharmaceuticals to Participate in September Investor Conferences

Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced participation in key healthcare conferences this September, inviting investors to join via webcast. Key events include the Baird Global Healthcare Conference on September 9 at 12:50 PM ET, H.C. Wainwright's 22nd Annual Global Investment Conference on September 14 at 10:30 AM ET, and the Cantor Fitzgerald Global Healthcare Conference on September 15 at 2:00 PM ET. All sessions will feature Scott Struthers, CEO. Recordings will be available on the company's website.

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:

Baird Global Healthcare Conference
	Date:		Wednesday, September 9th 2020
	Time:		12:50 pm Eastern Time
	Presenter:		Scott Struthers, Founder & CEO
H.C. Wainwright: 22nd Annual Global Investment Conference
	Date:		Monday, September 14th 2020
	Time:		10:30 am Eastern Time
	Presenter:		Scott Struthers, Founder & CEO
Cantor Fitzgerald Global Healthcare Conference
	Date:		Tuesday, September 15th 2020
	Time:		2:00 pm Eastern Time
	Presenter:		Scott Struthers, Founder & CEO

Webcast Links:
Links to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page in the Investors section on the Company’s website at www.crinetics.com.  

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 trial in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing an oral nonpeptide somatostatin receptor type 5 (sst5) agonist for hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company’s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company. For more information, please visit www.crinetics.com.

Contacts:										Media:
Marc Wilson										Aline Sherwood
Chief Financial Officer										Scienta Communications
IR@crinetics.com										asherwood@scientapr.com
(858) 450-6464										(312) 238-8957

FAQ

When will Crinetics Pharmaceuticals participate in the Baird Global Healthcare Conference?

Crinetics Pharmaceuticals will participate in the Baird Global Healthcare Conference on September 9, 2020, at 12:50 PM ET.

Who will present at the H.C. Wainwright Global Investment Conference for CRNX?

Scott Struthers, the CEO, will present at the H.C. Wainwright Global Investment Conference on September 14, 2020, at 10:30 AM ET.

What is the date and time for the Cantor Fitzgerald Global Healthcare Conference?

The Cantor Fitzgerald Global Healthcare Conference will take place on September 15, 2020, at 2:00 PM ET.

Where can I access the webcasts for Crinetics Pharmaceuticals' conference presentations?

Webcasts for Crinetics Pharmaceuticals' conference presentations will be available on the Events & Presentations page of their website.

What is Crinetics Pharmaceuticals focused on developing?

Crinetics Pharmaceuticals specializes in therapeutics for rare endocrine diseases and has a lead product candidate, paltusotine, for treating acromegaly.